Anna Thit Johnsen

Anna Thit Johnsen

Auto-generated profile, based on publicly available information

Anna Thit Johnsen

Institute of Psychology, University of Southern Denmark, Odense, Denmark

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2009 in European Journal of Haematology
Verified
Journal Article
Open access
PDF file
AJAnna T. Johnsen
Anna T. Johnsen
DTDorte Tholstrup
Dorte Tholstrup
MPMorten Aa. Petersen
Morten Aa. Petersen
LPLise Pedersen
Lise Pedersen
MGMogens Groenvold
Mogens Groenvold
Objectives:  Knowledge of health related quality of life of haematological patients is limited. This study aimed at investigating the prevalence and predictors of symptoms and problems in a representative sample of haematological patients in Denmark.Methods:  A random sample of patients with leukaemia, multiple myeloma and advanced lymphoma (n = 732) received the European Organisation for Research and Treatment of Cancer quality‐of‐life questionnaire (EORTC QLQ‐C30). Mean scores were calculated. In addition, scores were dichotomised using two thresholds: patients reporting at least ‘a little’ of each EORTC QLQ‐C30 symptom/problem were classified as having a ‘symptom/problem’, and patients reporting at least ‘quite a bit’ were classified as having a ‘severe symptom/problem’. Multiple logistic regression was used to identify predictors.Results:  In total, 470 (64%) patients participated. The most frequent symptoms/problems were fatigue (55%; severe 20%), reduced role function (49%; severe 23%), insomnia (46%; severe 15%), and pain (37%; severe 15%). Older patients and patients in active antineoplastic treatment had more symptoms and problems. There was only little evidence of social inequalities.Conclusion:  This is probably the first nationally representative study of symptoms and problems in haematological patients. These patients have symptoms/problems that deserve attention. Health related quality of life is an important issue in haematological malignancies.

13 November 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
IKIda J. Korfage
Ida J. Korfage
GCGiulia Carreras
Giulia Carreras
CCCaroline M. Arnfeldt Christensen
Caroline M. Arnfeldt Christensen
PBPascalle Billekens
Pascalle Billekens
LBLouise Bramley
Louise Bramley
JRJudith A. C. Rietjens
Judith A. C. Rietjens
Background: Advance care planning (ACP) supports individuals to define, discuss, and record goals and preferences for future medical treatment and care. Despite being internationally recommended, randomised clinical trials of ACP in patients with advanced cancer are scarce. Methods and findings: To test the implementation of ACP in patients with advanced cancer, we conducted a cluster-randomised trial in 23 hospitals across Belgium, Denmark, Italy, Netherlands, Slovenia, and United Kingdom in 2015–2018. Patients with advanced lung (stage III/IV) or colorectal (stage IV) cancer, WHO performance status 0–3, and at least 3 months life expectancy were eligible. The ACTION Respecting Choices ACP intervention as offered to patients in the intervention arm included scripted ACP conversations between patients, family members, and certified facilitators; standardised leaflets; and standardised advance directives. Control patients received care as usual. Main outcome measures were quality of life (operationalised as European Organisation for Research and Treatment of Cancer [EORTC] emotional functioning) and symptoms. Secondary outcomes were coping, patient satisfaction, shared decision-making, patient involvement in decision-making, inclusion of advance directives (ADs) in hospital files, and use of hospital care. In all, 1,117 patients were included (442 intervention; 675 control), and 809 (72%) completed the 12-week questionnaire. Patients’ age ranged from 18 to 91 years, with a mean of 66; 39% were female. The mean number of ACP conversations per patient was 1.3. Fidelity was 86%. Sixteen percent of patients found ACP conversations distressing. Mean change in patients’ quality of life did not differ between intervention and control groups (T-score −1.8 versus −0.8, p = 0.59), nor did changes in symptoms, coping, patient satisfaction, and shared decision-making. Specialist palliative care (37% versus 27%, p = 0.002) and AD inclusion in hospital files (10% versus 3%, p < 0.001) were more likely in the intervention group. A key limitation of the study is that recruitment rates were lower in intervention than in control hospitals. Conclusions: Our results show that quality of life effects were not different between patients who had ACP conversations and those who received usual care. The increased use of specialist palliative care and AD inclusion in hospital files of intervention patients is meaningful and requires further study. Our findings suggest that alternative approaches to support patient-centred end-of-life care in this population are needed. Trial registration: ISRCTN registry ISRCTN63110516.

14 May 2009 in Palliative Medicine
Verified
Journal Article
Closed access
AJAt Johnsen
At Johnsen
MPMa Petersen
Ma Petersen
LPL Pedersen
L Pedersen
MGM Groenvold
M Groenvold
Little is known about the need for palliative care among advanced cancer patients who are not in specialist palliative care. The purpose was to identify prevalence and predictors of symptoms and problems in a nationally representative sample of Danish advanced cancer patients. Patients with cancer stage 3 or 4 from 54 hospital departments (n = 1630) received the EORTC QLQ-C30 questionnaire. Mean scores were calculated according to the scoring manual and in addition a ‘symptom/problem’ and a ‘severe symptom/problem’ was defined and calculated. Multiple logistic regression was used to identify predictors. In total, 977 (60%) patients participated. The most frequent symptoms/problems were fatigue (57%; severe 22%) followed by reduced role function, insomnia and pain. Age, cancer stage, primary tumour, type of department, marital status and whether the patient had recently been hospitalized or not were associated with several symptoms and problems. This is probably the first nationally representative study of its kind. It shows that advanced cancer patients in Denmark have symptoms and problems that deserve attention and that some patient groups are especially at risk.

12 May 2017 in Palliative Medicine
Verified
Journal Article
Closed access
MGMogens Groenvold
Mogens Groenvold
MPMorten Aagaard Petersen
Morten Aagaard Petersen
ADAnette Damkier
Anette Damkier
MNMette Asbjoern Neergaard
Mette Asbjoern Neergaard
JNJan Bjoern Nielsen
Jan Bjoern Nielsen
AJAnna Thit Johnsen
Anna Thit Johnsen
Beneficial effects of early palliative care have been found in advanced cancer, but the evidence is not unequivocal. To investigate the effect of early specialist palliative care among advanced cancer patients identified in oncology departments. The Danish Palliative Care Trial (DanPaCT) (ClinicalTrials.gov NCT01348048) is a multicentre randomised clinical trial comparing early referral to a specialist palliative care team plus standard care versus standard care alone. The planned sample size was 300. At five oncology departments, consecutive patients with advanced cancer were screened for palliative needs. Patients with scores exceeding a predefined threshold for problems with physical, emotional or role function, or nausea/vomiting, pain, dyspnoea or lack of appetite according to the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) were eligible. The primary outcome was the change in each patient’s primary need (the most severe of the seven QLQ-C30 scales) at 3- and 8-week follow-up (0–100 scale). Five sensitivity analyses were conducted. Secondary outcomes were change in the seven QLQ-C30 scales and survival. Totally 145 patients were randomised to early specialist palliative care versus 152 to standard care. Early specialist palliative care showed no effect on the primary outcome of change in primary need (−4.9 points (95% confidence interval −11.3 to +1.5 points); p = 0.14). The sensitivity analyses showed similar results. Analyses of the secondary outcomes, including survival, also showed no differences, maybe with the exception of nausea/vomiting where early specialist palliative care might have had a beneficial effect. We did not observe beneficial or harmful effects of early specialist palliative care, but important beneficial effects cannot be excluded.

30 July 2017 in Qualitative Health Research
Verified
Journal Article
Closed access
CJClara Joergensen
Clara Joergensen
TTThora G. Thomsen
Thora G. Thomsen
LRLone Ross
Lone Ross
SDSusanne M. Dietz
Susanne M. Dietz
STSigne Therkildsen
Signe Therkildsen
AJAnna T. Johnsen
Anna T. Johnsen
Empowerment is a concept of growing importance in cancer care, but little is known about cancer patients’ experiences of empowerment during follow-up. To explore this area, a qualitative systematic literature review was conducted in PubMed, CINAHL, and PsycINFO. A total of 2,292 papers were identified and 38 articles selected and included in the review. The thematic synthesis of the papers resulted in seven analytical themes being identified: empowerment as an ongoing process, knowledge is power, having an active role, communication and interaction between patients and health care professionals, support from being in a group, religion and spirituality, and gender. Very few articles explicitly explored the empowerment of cancer patients during follow-up, and the review identified a lack of attention to patients’ own understandings of empowerment, a lack of specific focus on empowerment during follow-up, and insufficient attention to collective empowerment, as well as ethnic, social, and gender differences.

1 January 2021 in Public Health
Verified
Journal Article
Closed access
JDJ. Dressler
J. Dressler
AJA.T. Johnsen
A.T. Johnsen
LML.J. Madsen
L.J. Madsen
MRM. Rasmussen
M. Rasmussen
LJLars N. Jorgensen
Lars N. Jorgensen